Short- and mid-term outcomes after redo surgical valve replacement

Table 3 The multivariable analyses of study outcomes

Outcome	Characteristics	HR [OR] (95% CI)^a	P value
30-day mortality^b
	Chronic kidney disease	22.50 (3.44, 196.00)	0.002
All-cause mortality^c
	Dyslipidemia	0.42 (0.18, 0.95)	0.036
	History of major bleeding	4.79 (1.75, 13.10)	0.002
	Chronic kidney disease	20.40 (5.59, 74.50)	< 0.001
	Stroke	2.80 (1.27, 6.17)	0.011
	Transvalvular leakage in biological prosthesis	0.07 (0.010, 0.056)	0.012
Composite of thrombosis of a valve, embolic events, and major hemorrhage^d
	Diabetes	4.33 (1.65, 11.40)	0.003
	NYHA functional class III/IV	0.07 (0.01, 0.53)	0.010
	Sex (male)	0.18 (0.05, 0.69)	0.012
	History of percutaneous coronary intervention	8.13 (1.56, 42.50)	0.013
Major adverse events^e
	Hypertension	2.90 (1.25, 6.72)	0.013
	NYHA functional class III, IV	0.24 (0.07, 0.82)	0.023

CI: Confidence interval, HR: Hazard ratio, OR: Odds ratio, NYHA: New York Heart Association
^aOR for 30-day mortality, HR for Other outcomes
^bThe Hosmer–Lemeshow goodness-of-fit test: \(({\chi }_{2}^{2}=4.55, \text{P}=0.102)\), AUC with 95% CI 0.82 (0.68 to 0.96)
^cProportional hazard assumption: \(({\upchi }_{4}^{2}=4.56,\text{ P}=0.47)\), C-Index with 95% CI 0.74 (0.68 to 0.89)
^dProportional hazard assumption: \(({\upchi }_{4}^{2}=3.13,\text{ P}=0.189)\), C-Index with 95% CI 0.78 (0.71 to 0.86)
^eProportional hazard assumption: \(({\upchi }_{4}^{2}=1.06,\text{ P}=0.591)\), C-Index with 95% CI 0.69 (0.63 to 0.81)

ISSN: 2047-783X